Results 31 to 40 of about 13,126,675 (165)

Using single-dose liposomal amphotericin B for cryptococcal meningitis induction therapy: nurse pearls and practical perspectives [version 1; peer review: 2 approved]

Wellcome Open Research
Background In Uganda where the burden of HIV-associated cryptococcal meningitis is high, conventional amphotericin B deoxycholate has been standard to manage patients with cryptococcal meningitis in research settings.
Richard Kwizera, Cynthia Ahimbisibwe, Jane Frances Ndyetukira, David B. Meya, Carol Namujju   +4 more
doaj   +1 more source

Noncovalent complexation of amphotericin-B with Poly(α-glutamic acid).

, 2013
A noncovalent complex of amphotericin B (AmB) and poly(α-glutamic acid) (PGA) was prepared to develop a safe and stable formulation for the treatment of leishmaniasis. The loading of AmB in the complex was in the range of ∼20-50%.
Croft, Simon L, Mohamed-Ahmed, Abeer HA, Simon L. Croft, Les, Karolina A, Karin Seifert, Seifert, Karin, Brocchini, Stephen, Stephen Brocchini, Abeer H. A. Mohamed-Ahmed, Karolina A. Les, Brocchini, S., Mohamed-Ahmed, A.H.A., Les, K.A., Seifert, K., Croft, S.L.   +14 more
core   +1 more source

Atrioventricular block related to liposomal amphotericin B [PDF]

, 2014
Atrioventricular block can occur in normal children, young adults or athletes. It is also associated with underlying heart disease or occurs as a drug adverse effect. Amphotericin B is used in the treatment of invasive fungal infections. Cardiac toxicity
Rebelo, M, Almeida, H, Nunes, P, Sanches, B   +3 more
core   +2 more sources

Unmasking a Rare Adverse Effect of Liposomal Amphotericin B in Renal Transplantation: Acute Pancreatitis

Indian Journal of Transplantation
Liposomal amphotericin B is a macrolide polyene antibiotic which is used to treat serious fungal infections. The common adverse effects of liposomal amphotericin B include nephrotoxicity, hypokalemia, hypomagnesemia, anemia, and anaphylaxis. We present a
U. Kaviya, A. Subhashini, S. Anupriya, Sheik Sultan Alavudeen, Subashri Mohanasundaram   +4 more
doaj   +1 more source

Amphotericin B in the management of COVID-19 associated mucormycosis [PDF]

, 2023
Background: Amphotericin B is considered the drug of choice for primary treatment of mucormycosis. During second wave of COVID-19 pandemic there was severe scarcity of liposomal amphotericin B. This study aims to determine role of various formulations of
Premachandran, Architha M., Sheeja, Arunima, Shivalingaiah, Pruthvi R., Godse, Ashwini, Chandrashekar, Ravishankar, Pruthvi R. Shivalingaiah, Ashwini Godse, Ravishankar Chandrashekar, Arunima Sheeja, Architha M. Premachandran   +9 more
core   +1 more source

Liposomal Amphotericin B (AmBisome) Treatment Schedule.

, 2013
Liposomal Amphotericin B (AmBisome) Treatment Schedule.
Joris Veltman (431438), Jordan Dimitrakoff (431442), Adam P. Fagin (147181), Theo S. Plantinga (164719), Emeric F. Bojarski (431436), Mihai G. Netea (105648), Alexander Hoischen (195016), Adam C. Strauss (431437), Victor J. Anciano Granadillo (431440), Stephen A. Allsop (431439), Arsani William (431441)   +10 more
core   +1 more source

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

BMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim, Marwa Ahmed El‐Naka, Wedad M. Nageeb, Atta Ullah Khan, Noura M. Seleem, Aliaa Abdelghafar, Doaa Zamel, Yang Liu, Qigai He, Wentao Li   +9 more
wiley   +1 more source

Liposomal amphotericin B and complement activation-related pseudoallergy (CARPA). [PDF]

Antimicrob Agents Chemother
Infusion reactions (tachycardia, hypertension, fever, etc.) associated with liposomal amphotericin B are common. Animal models have found complement activation responsible, yet the pathophysiology has not been evaluated in human patients.
Thompson GR, Sani GM, Donnelley MA, Figueroa JK, Ciuffetelli R, Trigg K, Arredondo J, Koff A, Nearing M, Loque IC, Bays DJ, Dandekar S.   +11 more
europepmc   +2 more sources

From nature to nanoscale: advances, challenges, and preclinical translation of nanofiber drug delivery systems containing plant‐derived active ingredients

Journal of the Science of Food and Agriculture, EarlyView.
Abstract Since the early 1960s, nanotechnology has been a critical area of science, allowing for the development of sophisticated nanomaterials. Nanofibers, one of the most widely used nanotechnological drug delivery systems, have emerged as a highly versatile platform within modern pharmaceutical sciences.
Heybet Kerem Polat, Yasin Turanlı, Nihat Kurt, Sefa Gözcü, Emre Tunçel, Hilal Bacanak, Eren Aytekin, Sedat Ünal   +7 more
wiley   +1 more source

Clinical Challenges in the Management of Leishmania/HIV Coinfection in a Nonendemic Area: A Case Report

Case Reports in Infectious Diseases, 2012
We report on a 37-year-old male HIV-positive patient with generalized cutaneous leishmaniasis undiagnosed for several years. Upon presentation, visceral leishmaniasis was diagnosed in addition to cutaneous manifestation of the disease.
K. Grabmeier-Pfistershammer, W. Poeppl, P. M. Brunner, K. Rappersberger, A. Rieger   +4 more
doaj   +1 more source